CDK4 and leukemia: BCR-ABL was shown to increase Cyclin D2 and CDK4 in Ph-positive lymphoid leukemia, explaining the enhanced sensitivity of the cells to palbociclib.[31] These findings emphasize the possibility of improving outcomes in leukemia therapy by combining palbociclib and imatinib.